

ONCOLOGY INTELLIGENCE

A Comprehensive Report for Decision Making

2013



840 Pages Covers

19 CANCER INDICATIONS
(Full coverage with market forecast)

170 + ORPHAN DRUG STATUS

210 + CANCER DRUG TARGETS

624 CANCER COMPANIES PROFILES

850 + ONCOLOGY FOCUSED DEALS

1650 + CANCER DRUGS IN DEVELOPMENT

2650 + ONCOLOGY CLINICAL DRUG INDICATIONS

TOP 10 COMPANIES DRUG DEVELOPMENT STRATEGIES

2012 CORPORATE ACTIONS & CLINICAL DRUG DEVELOPMENT UPDATES

Oncology Intelligence Report 2013 provides complete landscape on cancer drug development, by bringing more authentic data under evaluation and is designed in a manner to keep knowledge instant, clear and precise at your fingertips to identify all potential changes thus enhancing your understanding and decision support.

Report covers updated cancer treatment molecules and companies profiles holding developmental / marketing rights to these molecules. It also contains oncology focused deals, funding options and technology platforms, together to provide comprehensive picture on cancer drug discovery by eliminating non focused information. Further no information is duplicated to provide you with clear and actionable intelligence.

Complete Cancer Drug Developers Intelligence

- One of the largest updated data available, covering 624 cancer drug developers having 1650+ active cancer molecules in late preclinical & clinical development.
- Management profile (CXOs/Directors) of Companies with market capital as 31st Dec 2012.
- Individual company profiles in form of mini reports.
- Special focus on proprietary technologies, latest deals, partnering opportunities, investors, cancer drugs in development and much more.

Top 10 Drug Developers Vs Other Developers

- Clearly identify the cancer drug development strategies of Top 10 developers vs. others.
- Identify how large players are filling their cancer drug development pipeline/technology gaps.
- Clearly demark Who is developing What & Why?

Cancer Indications Market Forecast Intelligence

- Detailed PHIII/II/I pipeline analysis of all major cancer indications with development partners.
- Expected launch, market forecast, Top selling drugs and their market size for each major cancer indication.

Clinical Trials & Orphan Drugs Intelligence

- Clinical trial status for 2650+ cancer drug indications.
- Latest Trials update status as in Dec 2012.
- Identify the slow requiring vs. fast enrolling drugs for similar indications.
- Identify 176 active orphan drug status granted by FDA and EMEA or both.

(Recently updated excel sheet of clinical trials, with other complete details can be purchased at additional cost. Contact reports@omicsx.com for details)



Emerging Cancer Drug Targets Intelligence

- Description of 210+ cancer drug targets in development with special focus to protein kinases.
- Individual target's gene, protein family, sub-cellular locations, drugs in development and its known association with cancer.
- Clearly demark established vs emerging drug targets.

Preclinical Drugs and Technology Intelligence

- Nearly 600+ preclinical molecules described (exclude molecules in discovery & lead optimization stages).
- Well defined first in class molecules.
- Special focus on emerging technologies owned by preclinical companies, with description of technology, partners & investors.

Bio Partnering Intelligence

- Covers 850+ oncology focused partnering deals. (Elaborated in individual company's profile).
- Identify molecule/technologies available for partnering.
- Investors/Government agencies involved in cancer funding.

2012 Corporate Action Intelligence

- Mergers & Acquisitions (with deal focus and valuation size).
- Partnering & Collaborations.
- Oncology Assets Acquisition/Termination.
- Venture Funding/IPO/Corporate Grants etc.
- Key Management (CXO/Presidents) appointments.

(Kindly check Sample Pages and Table of Content to check complete details)

95 pages contains single page Infographics demonstrating the emergence of cancer pre-clinical companies and emergence of new cancer clusters worldwide. Section contains 161 cancer companies' profiles, having exclusive preclinical drug pipeline and having valid active drug updates.

Each company profile contains key contacts, year of incorporation, assets valuation, market cap with stock exchange/ticker number, short description on proprietary drug discovery / development technologies, technology partners; key investors; cancer treatment focused preclinical pipeline with drug targets and mechanism of drug action. Lead optimization & Drug discovery stage molecules with their targets and short description are also included with details of partnering opportunities.

8 pages Infographics describes 462 cancer clinical companies, their country wise distribution, year of incorporation, assets valuation and total employee size.

All together to provide the complete landscape of current and emerging cancer innovation clusters.

63 pages
Infographics and Tables are designed in a way to provide the complete insights of 1042 active clinical molecules in PH I / II / III clinical trials for cancer treatment. Complete drug details of monoclonal antibodies, Antibody drug conjugates, cancer vaccines, virus based therapies, recombinant & synthetic proteins, gene therapies, stem cell and other cell based therapies description. Includes 211 unique cancer drug targets covering Protein Kinases, TNF family, G-coupled receptors, Tumor Surface Antigens, Transcription factors, Cellular Metabolites, Development proteins etc. as cancer drug targets with individual target's gene, protein family cellular location/function and their established role in cancer along with drugs in clinical development for the target.

Top 10 companies target selection strategies. Emerging focus on kinases as target of choice with currently available kinase inhibitors & kinases in development well defined. Also includes Top 20 companies details in terms of molecules in development.


528 pages contains, 462 cancer clinical companies' profiles having active clinical pipeline. Each page profile is written in a mini report format and covers details of contact, key management; employee numbers; assets valuation, market cap with ticker no.; technological collaborations drug discovery / development proprietary platform, key investors, oncology focused partnering deals & agreements.

It also contains, company's complete active clinical drug pipeline, individual drug name(s), target, mechanism of action, *first in class*, SPA / fast track & orphan drug (FDA/EMEA) status; updated clinical trials, with links for all active cancer indications, last update status & company's cancer preclinical / discovery pipeline details with target description.

16 pages contains all year 2012 major oncology focused corporate actions including new drug approvals, M&A activity, funding (V.C / Private Equity / IPO / Grants); Assets partnering/ termination, Key Industry- Acad partnerships and key management appointments.

82 Pages contains Infographics, tables and featured boxes containing complete updates on clinical developmental profiles of 19 major cancer indications including Lung, Breast, Colorectal, Melanoma, Prostrate, Ovarian, Pancreatic, HCC, Gastric, Multiple Myeloma, Leukemia, NHL, Hodgkin Lymphoma, Brain, Head and Neck, RCC, Bladder, Thyroid and Sarcoma. Each profile contains epidemiology, market forecast, top selling chemotherapies & targeted therapies, PhIII pipeline drugs with their clinical trial design & combination drugs, key partners with expected launch. Also contains monoclonal antibodies, vaccine and biologics in development; complete PH II & PH I pipeline with partners.

Top 10 vs. other developer's strategies, total kinases in development for particular indication. Identify 2012 major drug advances, failures and new entrants.



CXOs / VPs / Directors

- Single source with validated data helps in identifying the crowdedness of the competitive space.
- Identify your drug's competitive position and potential partnering opportunities.
- Quickly navigate the complete profiles of competitors and their development strategies.
- Infographics design with focused and interactive content, takes no time in filling knowledge gaps.

Venture Capital Partners

- Identify Game-changing therapeutics, that address unmet medical needs.
- De-risk the venture by getting real insights and sourcing new valuable deals.
- Identify the paradigm shift in cancer drug discovery (Large Pharma vs. Small Innovators).
- Virtually cover all oncology focused partnering deals occurs in past few years with their valuation sizes.

Investors / Analysts

- Eliminate your hours of search and data curation; and spend more time in analyzing details & making decisions.
- Compare orange to oranges and apple to apples for strategic assessment of oncology drug developing companies.
- Bring more data under analysis for complete picture.
- Forecast the real impact of molecule/asset acquisition or termination effects on company's valuation size.

Drug Developers

- Outlines robust number of active drugs (1600+) for cancer treatment with individual drug's mechanism of action.
- Check all cancer drug targets in clinical development and demark between established and emerging targets.
- Analyze emerging drug technologies and preclinical research preferences among biologics & small molecules.
- Identify first in class and best in class molecules in development stages & predict the future of cancer drug discovery.

Clinical Trial Managers

- Summary information of all valid trials with 'last update status' and valid link to government databases.
- View the clinical trials landscape in the context of your own activities as well as competitors.
- Identify drug withdrawals due to slow recruiting status and other failures.
- Analyze how big pharma stepwise project multiple trials for different indications, to their prospect molecules.

Entrepreneurs / Emerging Players

- Reveal the untapped areas in cancer drug discovery.
- Identify cancer indications, which need more attention and drugs that may be a game changer going ahead.
- Partnering with right technology company to access clinical development needs.

Sales / Marketing Executives

- Identify present and emerging market size with forecast on all major cancer indications.
- Explore Top selling targeted/chemotherapy drugs for individual cancer indication and its market size.
- Expected PH III launch for 19 major cancer indications with line of therapy & clinical trial combinations, together helps in predicting market threats and size till 2020.

CRO / BioSuppliers / Technology Incubators

- Discover and pursue various focused business development opportunities.
- Complete company's addresses, drug development plan, funding status and management team.
- Identify the clinical development needs of drug developing companies.

	Oncology Intelligence 2013 Most Updated	Other Reports	Other Databases
Layout	Infographics/ Tables / Figures / Featured Boxes	Figures & Tables (usually)	Figures & Tables (usually)
Design	Interactive colourful Magazine (easy to read)	Simple Designs	Interactive Simple Designs
Updates	Regularly*	Occasionally	Regularly
Companies Coverage (Clinical)	462 [!]	250-300 Clinical Companies	300-350 Clinical Companies
Companies Coverage (Exclusive PreClinical)	162 [!]	Usually preclinical data is not the part of reports	30-40 exclusive preclinical companies
Platform Technologies Details	✓ (340+ Technology Platforms discussed)	✗	✗
Clinical Drugs in Development	1042 active cancer treatment drugs	500-600 cancer cure & cancer care drugs	800-900 cancer cure & cancer care drugs
Preclinical Drug Coverage	610 + (active late preclinical molecules)	100-150 molecules	200-250 molecules
Individual Drug's Mechanism of Actions	✓	✗	✗
First In Class Details	✓	Limited	Limited
Oncology Orphan Drugs	Yes (176 active orphan status)	Yes (Limited Indications)	Yes (Limited Indications)
Cancer Drug Target Details	211	No detailed	No detailed
Total Cancer Indication Coverage in Single Report	19 (Cancer Indications full coverage)	5-6 Cancer Indication Coverage	Main Cancer Indications Coverage
Detailed Pipeline (PH III/PH II/PH I)	✓	usually Ph III and Ph II	✓
Individual Drug's all Active Clinical Indications with Trials Update Status	✓	✗	✗
Top 10 Companies Drug Development Strategies	✓	✗	✗
Market Forecast	✓	✓	✓
Oncology Focused Deals (with size and details)	860 + Deals	300+ Deals	500+ Deals
Country Coverage	Worldwide	US and Europe mainly	US and Europe mainly
2012 Corporate Actions	✓	✗	Limited
Full Referances for the validation of Data	✓	✗	Limited
Major Emphasis	Avoid Data Duplication and bring more data under analysis		Bring more disease areas on the same platform
Price in USD	3499 USD	approx 4500 USD	approx 25000 USD <small>annual subscription</small>

* Starting Jan 2013, Oncology Intelligence will be published twice every year. The regular subscribers get **50% discount** on the cover price for subsequent purchases. For more details on offer refer to Terms and Conditions and mail to reports@omicsx.com

! Non Active clinical/pre-clinical trials molecules or companies with such data are not considered. Also only cancer cure molecules/companies are profiled. No cancer care/cancer management molecules are counted/profiled.

ONCOLOGY INTELLIGENCE - A Comprehensive Report for Decision Making 2013

YES, I WOULD LIKE TO PURCHASE NOW

Product Name: Oncology Intelligence 2013**Published by:** HH Biotechnologies Pvt. Ltd.**Single user price:** \$3499.00**Product Type:** Intelligence Report (840 pages)**Product Code:** OI2013**Email:** reports@omicsx.com**Product Link:** www.omicsx.com/reports.html**Published on:** 24th January 2013**Online Purchases:** [Click Here](#)**Payment**

To pay by Credit Card (PayPal, Visa, MasterCard, American Express), please, click 'BUY NOW' button on report page

<http://omicsx.com/reports.html>**Your Details: (Please use BLOCK CAPITALS)**Title: Dr Mr Ms

First Name: _____

Last Name: _____ Middle Name: _____

Department: _____

Position: _____

Company: _____

Address: _____

_____ State/Province _____

Country: _____ Postcode/Zip: _____

Tel: _____ Fax: _____

Mobile No: _____

Email: _____

Please sign below to confirm your order

Date: _____ Signature _____

(All orders must be signed by authorised signatory)

Mail this completed order form to:

HH Biotechnologies Pvt. Ltd.

Biotech Park, Sector-G, Jankipuram,

Lucknow, INDIA.

E-mail: reports@omicsx.com **Online:** www.omicsx.com

If you required Corporate License or other details, Kindly contact our Customer Service: contact@omicsx.com

Stay Legal: Terms & Conditions

In placing an order you agree not to hand-on or otherwise communicate this report in whole or part to any 3rd party whatsoever by any means or any access.

*Our full terms and conditions related to the sale of this report please [click here....](#)***Coming Soon....****A Comprehensive Intelligence on Oncology Drug Funding - 2013**

Report covers the complete cancer drug development funding scenario and details of 350+ focused VCs with prior exposure to oncology funding.

Releasing March 2013**SALES CONTACT NUMBERS**

USA	+1 646 513 4433
UK	+44 203 608 3536
Asia	+91 562 228 1122

FAX BACK THIS FORM TO

USA	+1 646 568 9962
UK	+44 203 608 3487
Asia	+91 562 228 1099